MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Huntingtons disease"

  • 2017 International Congress

    Loss of PDE10A expression in patients with PDE10A and ADYC5 mutations

    F. Niccolini, N. Mencacci, E. Rabiner, V. Salpietro, G. Pagano, B. Balint, H. Houlden, R. Gunn, N. Wood, K. Bhatia, M. Politis (London, United Kingdom)

    Objective: To assess phosphodiesterase 10A (PDE10A) expression in vivo, using [11C]IMA107 PET in patients with PDE10A and adenylate cyclase 5 (ADYC5) mutations. Background: Cyclic adenosine…
  • 2017 International Congress

    The Long-Term Safety of Deutetrabenazine for Chorea in Huntington Disease

    S. Frank, C. Vaughan, D. Stamler, D. Oakes, M. Davis, S. Eberly, E. Kayson, J. Whaley, J. Goldstein, C. Testa (Boston, MA, USA)

    Objective: To evaluate the safety and tolerability of deutetrabenazine in Huntington Disease (HD) over long term exposure. Background: In a randomized, double-blind, controlled trial (First-HD),…
  • 2017 International Congress

    Clinical and genetic characterization of Huntington’s disease in relation to the age and type of onset.

    L. Mendoza Vega, M. Rodríguez-Violante, A. Cervantes-Arriaga, A. De-la-Cruz-Landero, N. Davila-Avila, K. Salinas-Barboza, S. Isais-Millan (Mexico City, Mexico)

    Objective: To describe the clinical features and CAG repeats in a large population of Mexican patients with Huntington's disease and its relation to the age…
  • 2017 International Congress

    Long-Term Dopamine Transporter Imaging and Clinical Effects of the Mixed-Lineage Kinase Inhibitor CEP-1347 in the PRECEPT Parkinson Trial

    I. Shoulson, S.E. Eberly, D. Oakes, A. Lang, M. Schwarzschild, C. Tanner, J. Seibyl, K. Marek (Washington, DC, USA)

    Objective: To assess the imaging and clinical effects of CEP-1347 after treatment discontinuation  in the Parkinson Research Examination of CEP-1347 Trial (PRECEPT), a multi-center randomized…
  • 2017 International Congress

    The Huntington’s Disease Health Index Study (HD-HI)

    A. Glidden, E. Luebbe, M. Elson, S. Goldenthal, R. Dorsey, C. Heatwole (Rochester, NY, USA)

    Objective: To identify the symptomatic domains with the greatest impact on quality-of-life for those living with Huntington’s Disease (HD) through patient and caregiver interviews. Background:…
  • 2017 International Congress

    Prescription pattern of treatment in Mexican patients with Huntington’s Disease.

    A. De-la-Cruz, L. Mendoza Vega, N. Davila Avila, K. Salinas Barboza, S. Isais Millan, A. Cervantes Arriaga, M. Rodriguez Violante (Ciudad de Mexico, Mexico)

    Objective: To describe the prescription pattern for the treatment of HD in a sample of Mexican patients from a tertiary referral center. Background: Huntington’s disease…
  • 2017 International Congress

    Syndenham’s chorea in Senegalese children: A case series

    F.S. NGOUNGOURE HALIMA, M. NDIAYE, A.D. SOW, B. SECK, M.M. NDIAYE (Dakar, Senegal)

    Objective: To describe clinical profile and treatment outcome of Sydenham’s chorea (SC) in children attending a tertiary care hospital in Dakar, Senegal. Background: SC is…
  • 2017 International Congress

    Behavioral Changes on the UCSD Huntington’s Disease Behavioral Questionnaire (HD-BQ) Distinguish Patients Transitioning to Manifest Huntington’s disease (HD)

    S. Park, S. Nam, A. Nathan, A. Haque, A. Haque, P. Gilbert, J. Corey-Bloom (La Jolla, CA, USA)

    Objective: To utilize the UCSD Huntington's Disease Behavioral Questionnaire (HD-BQ) to assess behavioral changes that distinguish HD gene carriers transitioning to manifest HD. Background: Behavioral…
  • 2017 International Congress

    Prevalence of substance abuse in Huntington´s disease patients and its relationship with neuropsychiatric symptoms

    K. SALINAS BARBOZA, L. MENDOZA VEGA, A. CRUZ LANDERO, S. ISAIS MILLAN, M. RODRIGUEZ VIOLANTE, A. CERVANTES ARRIAGA, N. DAVILA AVILA (MEXICO, Mexico)

    Objective: To describe the prevalence of substance abuse and its relationship with neuropsychiatric features in Huntington’s disease (HD). Background: Substance abuse is not well established…
  • 2017 International Congress

    Juvenile Huntington Disease (JHD) subjects’ stratification according to the mutation-length

    M. Marano, M. Marano, S. Migliore, S. Maffi, F. Consoli, A. Ciammola, E. Gatto, F. Squitieri (Rome, Italy)

    Objective: To identify clinical and genetic markers to differ JHD from adult Huntington disease (HD) and to monitor JHD progression Background: JHD is a HD…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 11
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • Life expectancy with and without Parkinson’s disease in the general population
  • Nilotinib for treating MSA: A preclinical proof of concept study
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley